Molecular Profiling Is Rather Likely to Be Cost Effective

Valesca P. Retèl, Sabine C. Linn, Wim H. van Harten

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
145 Downloads (Pure)


In a recent report, Bonastre et al1 calculated the cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer and concluded that, under the present circumstances in France, the 70-gene signature (MammaPrint) is unlikely to be cost effective.
Original languageEnglish
Pages (from-to)1626-1627
JournalJournal of clinical oncology
Issue number14
Publication statusPublished - 2015


Dive into the research topics of 'Molecular Profiling Is Rather Likely to Be Cost Effective'. Together they form a unique fingerprint.

Cite this